Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Eiger BioPharmaceuticals, a biopharmaceutical company focused on therapies for hepatitis delta virus, announced its participation in three investor conferences. Key details include:
Citi's 17th Annual BioPharma Conference on September 8, 2022, in Boston, format: one-on-one meetings.
H.C. Wainwright 24th Annual Global Investment Conference scheduled for September 12 at 2:00 p.m. ET in New York, with presentations and meetings.
Baird Global Healthcare Conference on September 14 at 3:45 p.m. ET, also in New York. Live webcasts available on the company's website.

PALO ALTO, Calif., Sept. 1, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its management team will participate in the following upcoming investor conferences:

Citi's 17^th Annual BioPharma Conference

• Date: Thursday, September 8, 2022
• Location: Boston, MA
• Format: One-on-one meetings

H.C. Wainwright 24^th Annual Global Investment Conference

• Date & Time: Monday, September 12, 2022 at 2:00 p.m. ET
• Location: New York, NY
• Format: Company presentation and one-on-one meetings

Baird Global Healthcare Conference

• Date & Time: Wednesday, September 14, 2022 at 3:45 p.m. ET
• Location: New York, NY
• Format: Company presentation and one-on-one meetings

A live webcast of each presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at www.eigerbio.com. A replay of each presentation will be available on the website for at least 90 days. 

About Eiger

Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com 

Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-three-upcoming-investor-conferences-301616160.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

When is EIGR participating in Citi's 17th Annual BioPharma Conference?

Eiger BioPharmaceuticals will participate in Citi's 17th Annual BioPharma Conference on September 8, 2022, in Boston.

What is the schedule for EIGR at the H.C. Wainwright 24th Annual Global Investment Conference?

Eiger BioPharmaceuticals is scheduled for the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 2:00 p.m. ET in New York.

When will EIGR present at the Baird Global Healthcare Conference?

Eiger BioPharmaceuticals will present at the Baird Global Healthcare Conference on September 14, 2022, at 3:45 p.m. ET in New York.

Will EIGR's presentations be available online?

Yes, Eiger BioPharmaceuticals will offer live webcasts of each presentation on its Investors website, with replays available for 90 days.

What is the focus of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals focuses on developing innovative therapies for hepatitis delta virus and other serious diseases.